DermTech Dividendos y recompras

Dividendo controles de criterios 0/6

DermTech no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

-15,374,285.7%

Rendimiento de la recompra

Rendimiento total para el accionista	-15,374,285.7%
Rendimiento futuro de los dividendos	n/a
Crecimiento de los dividendos	n/a
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Ratio de pago	n/a

Últimas actualizaciones de dividendos y recompras

No hay actualizaciones

Recent updates

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

May 21

We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

Mar 02

Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%

Mar 02

Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023

May 10

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%

May 06

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Jan 16

Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

Nov 08

Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

Oct 11

DermTech grants stock options

Oct 11

Diving Into DermTech

Sep 01

Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

Aug 10

DermTech: Approaching An All Or Nothing Moment

Jun 13

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Jun 04

DermTech - Taking A Second Look At The Growth Thesis

Mar 31

DermTech: Adoption Headwinds And Earnings Misses

Dec 23

Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth

Dec 02

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de DMTK.Q han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de DMTK.Q han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de DermTech vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de DMTK.Q con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (DMTK.Q)	n/a
Suelo de mercado 25% (US)	1.4%
Techo de mercado 25% (US)	4.2%
Media de la industria (Biotechs)	2.3%
Analista de previsiones (DMTK.Q) (hasta 3 años)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de DMTK.Q en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de DMTK.Q en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de DMTK.Q para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que DMTK.Q no ha comunicado ningún pago.

DermTech Dividendos y recompras

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos y recompras

Recent updates

DermTech, Inc.(NasdaqCM:DMTK) dropped from NASDAQ Composite Index

Nasdaq to Delist Common Stock of DermTech

Motion for Joint Administration Filed by DermTech, Inc.

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

Kilroy Realty, L.P. Files a Complaint Against DermTech, Inc. for $661,706 in Unpaid Rent

First quarter 2024 earnings released: US$0.58 loss per share (vs US$1.02 loss in 1Q 2023)

Price target decreased by 26% to US$2.04

DermTech Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Minimum Bid Price Requirement

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target decreased by 11% to US$3.20

We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

DermTech, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer

DermTech Announces Positive Topline Results from A Study Evaluating the Dermtech Melanoma Test (Dmt) Across All Skin Types

DermTech, Inc. Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-On Assay

Dermtech Announces Positive Topline Results from Trust 2 Study Evaluating the Dermtech Melanoma Test (Dmt)

Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price

Pomerantz LLP Announces the Filing of A Class Action Against DermTech, Inc. and Certain Officers

Consensus EPS estimates upgraded to US$3.11 loss

Third quarter 2023 earnings: EPS exceeds analyst expectations

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against DermTech, Inc

DermTech, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky

Dermtech Appoints Mark Aguillard as Chief Commercial Officer

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

DermTech, Inc. to Report Q2, 2023 Results on Aug 03, 2023

DermTech, Inc. Announces the Todd Wood’s Last Day of Employment as Chief Commercial Officer Will Be July 3, 2023

DermTech, Inc. Announces ECRI Complete Its Evaluation of the Pigmented Lesion Assay

Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?

Consensus revenue estimates fall by 16%

Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023

DermTech, Inc. Announces Change of CEO

Price target decreased by 22% to US$5.75

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%

First quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 11% to US$7.00

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

DermTech, Inc. to Report Q4, 2022 Results on Mar 02, 2023

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

DermTech, Inc. Announces the Foundational Assay of Its DermTech Melanoma Test Is Recommended for Coverage by TRICARE

DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its Dermtech Melanoma Test (Dmt)

Price target decreased to US$7.33

High number of new directors

DermTech, Inc. Announces Board Committee Appointments

Consensus forecasts updated

Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

DermTech, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

DermTech grants stock options

Diving Into DermTech

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

Dermtech, Inc. Provides Revenue Guidance for the Full Year 2022

DermTech, Inc. Appoints Chief Compliance Officer and SVP of Research and Development

DermTech, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Dermtech Announces New Board Appointment

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2000 Dynamic Index

DermTech: Approaching An All Or Nothing Moment

President exercised options to buy US$59k worth of stock.

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

High number of new and inexperienced directors

DermTech, Inc. Presents New Research Differentiating Atopic Dermatitis and Psoriasis At the Society for Investigative Dermatology's Annual Meeting

DermTech, Inc. Affirms Revenue Guidance for the Full-Year 2022

DermTech, Inc., Annual General Meeting, May 26, 2022

DermTech - Taking A Second Look At The Growth Thesis

DermTech, Inc. announced delayed annual 10-K filing

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

DermTech, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

DermTech, Inc. to Report Q4, 2021 Results on Mar 01, 2022

DermTech: Adoption Headwinds And Earnings Misses

Chief Commercial Officer notifies of intention to sell stock